Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 48, Issue 3, 2015, Pages 637-646

  Åberg, Daniel ^a   Johansson, Per ^a,b   Isgaard, Jörgen ^a,c   Wallin, Anders ^a   Johansson, Jan Ove ^a   Andreasson, Ulf ^a   Blennow, Kaj ^a   Zetterberg, Henrik ^a,d   Åberg, N David ^a   Svensson, Johan ^a   Baker, Laura ^a,e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SKARABORG HOSPITAL   (Sweden)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e SKARABORG HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; IGF II; IGFBP 1; IGFBP 2; mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IGF2 PROTEIN, HUMAN; IGFBP-2 PROTEIN, HUMAN; IGFBP1 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; STABLE MILD COGNITIVE IMPAIRMENT; BLOOD; CEREBROSPINAL FLUID; PHOSPHORYLATION; SEXUAL DEVELOPMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR II; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SEX CHARACTERISTICS; TAU PROTEINS;

EID: 84943802298     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150351     Document Type: Article

References (42)

1. Russo V, Gluckman P, Feldman E, Werther G (2005) The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 26, 916-943.
2. O'Kusky J, Ye P (2012) Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol 33, 230-251.
3. Tham A, Nordberg A, Grissom F, Carlsson-Skwirut C, Viitanen M, Sara V (1993) Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 5, 165-176.
4. Wilczak N, Schaaf M, Bredewold R, Streefland C, Teelken A, DeKeyser J (1998) Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. Neurosci Lett 257, 168-170.
5. Bunn R, King W, Winkler M, Fowlkes J (2005) Early developmental changes in IGF-I, IGF-II, IGF binding protein-1, and IGF binding protein-3 concentration in the cerebrospinal fluid of children. Pediatr Res 58, 89-93.
6. Salehi Z, Mashayekhi F, Naji M (2008) Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors 33, 99-106.
7. Mashayekhi F, Mirzajani E, Naji M, Azari M (2010) Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci 17, 623-627.
8. Fernandez A, Torres-Alemán I (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13, 225-239.
9. Hawkes C, Kar S (2004) The insulin-like growth factor-II/mannose-6 phosphate receptor: Structure, distribution and function in the central nervous system. Brain Res Brain Res Rev 44, 117-140.
10. Hawkes C, Jhamandas J, Harris K, Fu W, MacDonald R, Kar S (2006) Single transmembrane domain insulinlike growth factor-II/mannose-6-phosphate receptor regulates central cholinergic function by activating a G-proteinsensitive, protein kinase C-dependent pathway. J Neurosci 26, 585-596.
11. de la Monte S (2012) Triangulated mal-signaling in Alzheimer's disease: Roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis 30(Suppl 2), S231-S249.
12. Carro E, Trejo J, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8, 1390-1397.
13. Carro E, Trejo SC, Antequera JL, Torres-Aleman D, I (2005) Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 25, 10884-10893.
14. Rivera E, Goldin A, Fulmer N, Tavares R, Wands J, de la Monte S (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
15. Steen E, Terry B, Rivera E, Cannon J, Neely T, Tavares R, Xu X, Wands J, de la Monte S (2005) Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
16. Talbot K, Wang H, Kazi H, Han L, Bakshi KP, Stucky A, Fuino R, Kawaguchi K, SamoyednyA, Wilson R, Arvanitakis Z, Schneider J, Wolf B, Bennett D, Trojanowski J, Arnold S (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
17. Hertze J, Nägga K, Minthon L, Hansson O (2014) Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: An observational study. BMC Neurol 14, 64.
18. Chen D, Stern S, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer R, Alberini C (2011) A critical role for IGF-II in memory consolidation and enhancement. Nature 469, 491-497.
19. Amritraj A, Rauw G, Baker G, Kar S (2010) Leu27 insulin-like growth factor-II, an insulin-like growth factor-II analog, attenuates depolarization-evoked GABArelease from adult rat hippocampal and cortical slices. Neuroscience 170, 722-730.
20. Green C, Holly J, Bayer A, Fish M, Ebrahim S, Gallacher J, Ben-Shlomo Y (2014) The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging and dementia risk: The Caerphilly Prospective Study. J Alzheimers Dis 41, 867-875.
21. Pascual-Lucas M, Viana da Silva S, Di Scala M, Garcia-Barroso C, González-Aseguinolaza G, Mulle C, Alberini C, Cuadrado-Tejedor M, Garcia-Osta A (2014) Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med 6, 1246-1262.
22. Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T (2013) Galantamine increases hippocampal insulin-like growth factor 2 expression via -7 nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) 225, 543-551.
23. Schmeisser M, Baumann B, Johannsen S, Vindedal G, Jensen V, Hvalby Ø, Sprengel R, Seither J, Maqbool A, Magnutzki A, Lattke M, Oswald F, Boeckers T, Wirth T (2012) I-B kinase/nuclear factor -B-dependent insulin-like growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling. J Neurosci 32, 5688-5703.
24. Stern S, Kohtz A, Pollonini G, Alberini C (2014) Enhancement of memories by systemic administration of insulin-like qrowth factor II. Neuropsychopharmacology 39, 2179-2190.
25. Mellott T, Pender S, Burke R, Langley E, Blusztajn J (2014) IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. PLoS One 9, e94287.
26. Johansson P, Åberg D, Johansson J-O, Mattsson N, Hansson O, Ahrén B, Isgaard J, Åberg N, Blennow K, Zetterberg H, Wallin A, Svensson J (2013) Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology 38, 1729-1737.
27. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490, 127-133.
28. Trueba-Sáiz A, Cavada C, Fernandez A, Leon T, González D, Fortea Ormaechea J, Lleó A, Del Ser T, Nuñez A, Torres-Aleman I (2013) Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry 3, e330.
29. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson J, Andreasson U, Zetterberg H, Blennow K, Svensson J (2011) Cerebrospinal fluid biomarkers for Alzheimer's disease: Diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 24, 537-546.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
31. Román G, Tatemichi T, Erkinjuntti T, Cummings J, Masdeu J, Garcia J, Amaducci L, Orgogozo J, Brun A, Hofman A, Moody M, O'Brien M, Yamaguchi T, Grafman J, Drayer B, Bennett D, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf P, Gorelick P, Bick K, Pajeau A, Bell M, DeCarli C, Culebras A, Korczyn A, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
32. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, RomanG, Chui H, DesmondD(2000) Research criteria for subcortical vascular dementia in clinical trials. Neural Transm Suppl 59, 23-30.
33. Petersen R (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
34. Folstein M, Folstein S, McHugh P (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
35. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse M, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
36. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245.
37. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
38. Logan A, Gonzalez A, Hill D, Berry M, Gregson N, Baird A (1994) Coordinated pattern of expression and localization of insulin-like growth factor-II (IGF-II) and IGFbinding protein-2 in the adult rat brain. Endocrinology 135, 2255-2264.
39. Frank H, PardridgeW, MorrisW, Rosenfeld R, Choi T (1986) Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes 35, 654-661.
40. Duron E, Funalot B, Brunel N, Coste J, Quinquis L, Viollet C, Belmin J, Jouanny P, Pasquier F, Treluyer J-M, Epelbaum J, le Bouc Y, Hanon O (2012) Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease. J Clin Endocrinol Metab 97, 4673-4681.
41. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T, Arnold G, Lahm H, Kolb H, Wolf E (1999) Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 140, 5488-5496.
42. Hoeflich A, Nedbal S, Blum W, Erhard M, Lahm H, Brem G, Kolb H, Wanke R, Wolf E (2001) Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 142, 1889-1898.